Can we predict tuberculosis cure? What tools are available?

Delia Goletti, Cecilia S. Lindestam Arlehamn, Thomas J. Scriba, Richard Anthony, Daniela Maria Cirillo, Tonino Alonzi, Claudia M. Denkinger, Frank Cobelens

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of "cure". Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.

Original languageEnglish
JournalThe European respiratory journal
Volume52
Issue number5
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Tuberculosis
Recurrence
Therapeutics
Pulmonary Tuberculosis
Mycobacterium tuberculosis
Bacillus
Pneumonia
Biomarkers
Anti-Bacterial Agents
Health
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Can we predict tuberculosis cure? What tools are available? / Goletti, Delia; Lindestam Arlehamn, Cecilia S.; Scriba, Thomas J.; Anthony, Richard; Cirillo, Daniela Maria; Alonzi, Tonino; Denkinger, Claudia M.; Cobelens, Frank.

In: The European respiratory journal, Vol. 52, No. 5, 01.11.2018.

Research output: Contribution to journalReview article

Goletti, Delia ; Lindestam Arlehamn, Cecilia S. ; Scriba, Thomas J. ; Anthony, Richard ; Cirillo, Daniela Maria ; Alonzi, Tonino ; Denkinger, Claudia M. ; Cobelens, Frank. / Can we predict tuberculosis cure? What tools are available?. In: The European respiratory journal. 2018 ; Vol. 52, No. 5.
@article{76f13d053de1461ab45c179c1c88077a,
title = "Can we predict tuberculosis cure? What tools are available?",
abstract = "Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of {"}cure{"}. Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.",
author = "Delia Goletti and {Lindestam Arlehamn}, {Cecilia S.} and Scriba, {Thomas J.} and Richard Anthony and Cirillo, {Daniela Maria} and Tonino Alonzi and Denkinger, {Claudia M.} and Frank Cobelens",
year = "2018",
month = "11",
day = "1",
doi = "10.1183/13993003.01089-2018",
language = "English",
volume = "52",
journal = "European Journal of Respiratory Diseases",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

TY - JOUR

T1 - Can we predict tuberculosis cure? What tools are available?

AU - Goletti, Delia

AU - Lindestam Arlehamn, Cecilia S.

AU - Scriba, Thomas J.

AU - Anthony, Richard

AU - Cirillo, Daniela Maria

AU - Alonzi, Tonino

AU - Denkinger, Claudia M.

AU - Cobelens, Frank

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of "cure". Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.

AB - Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of "cure". Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.

UR - http://www.scopus.com/inward/record.url?scp=85056413908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056413908&partnerID=8YFLogxK

U2 - 10.1183/13993003.01089-2018

DO - 10.1183/13993003.01089-2018

M3 - Review article

VL - 52

JO - European Journal of Respiratory Diseases

JF - European Journal of Respiratory Diseases

SN - 0903-1936

IS - 5

ER -